Collegium Competitors
| COLL Stock | USD 45.28 0.14 0.31% |
Collegium Pharmaceutical vs Nektar Therapeutics Correlation
Very good diversification
The correlation between Collegium Pharmaceutical and NKTR is -0.21 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Collegium Pharmaceutical and NKTR in the same portfolio, assuming nothing else is changed.
Moving against Collegium Stock
Return On Tangible Assets is expected to rise to 0.11 this year. Return On Capital Employed is expected to rise to 0.14 this year. At this time, Collegium Pharmaceutical's Intangible Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 0.11 this year, although the value of Net Tangible Assets are projected to rise to (432.9 M).Collegium Pharmaceutical Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Collegium Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Collegium and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Collegium Pharmaceutical does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Collegium Stock performing well and Collegium Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Collegium Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AMPH | 1.93 | 0.12 | 0.07 | 0.15 | 2.09 | 4.12 | 15.04 | |||
| DVAX | 1.69 | 0.75 | 0.47 | (11.62) | 0.44 | 2.76 | 39.08 | |||
| CRON | 2.07 | 0.06 | 0.01 | 0.21 | 2.27 | 3.72 | 21.46 | |||
| GDRX | 2.16 | (0.61) | 0.00 | (0.35) | 0.00 | 3.44 | 15.98 | |||
| INVA | 1.01 | 0.08 | 0.03 | 0.29 | 1.14 | 2.29 | 8.53 | |||
| PCRX | 2.08 | (0.07) | 0.00 | (0.01) | 0.00 | 3.31 | 14.20 | |||
| MDXG | 1.76 | (0.62) | 0.00 | (0.62) | 0.00 | 3.21 | 10.23 | |||
| PLSE | 3.66 | 0.54 | 0.21 | 0.20 | 2.94 | 7.62 | 52.77 | |||
| ATAI | 2.77 | (0.34) | 0.00 | (0.18) | 0.00 | 5.77 | 15.30 | |||
| NKTR | 4.68 | 0.58 | 0.11 | 0.99 | 4.90 | 8.03 | 32.58 |
Cross Equities Net Income Analysis
Compare Collegium Pharmaceutical and related stocks such as Amphastar P, Dynavax Technologies, and Cronos Group Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVAX | (26.7 M) | (48.6 M) | (69.9 M) | (66.7 M) | (90.7 M) | (106.8 M) | (112.4 M) | (95.2 M) | (158.9 M) | (152.6 M) | (75.2 M) | 76.7 M | 293.2 M | (6.4 M) | 27.3 M | 31.4 M | 33 M |
| CRON | (619.5 K) | (619.5 K) | (619.5 K) | (619.5 K) | (4.2 M) | 278.3 K | (885 K) | (1.5 M) | (21.6 M) | 1.2 B | (73.1 M) | (396.1 M) | (168.7 M) | (74 M) | 41.1 M | 37 M | 31.1 M |
| GDRX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | 8.8 M | 43.8 M | 66 M | (293.6 M) | (25.3 M) | (32.8 M) | (8.9 M) | 16.4 M | 14.8 M | 15.5 M |
| INVA | (94.9 M) | (115.3 M) | (18.5 M) | (170.7 M) | (168.5 M) | (18.8 M) | 59.5 M | 134.1 M | 395.1 M | 157.3 M | 224.4 M | 265.9 M | 213.9 M | 179.7 M | 23.4 M | 26.9 M | 28.2 M |
| PCRX | (41.9 M) | (43.3 M) | (52.3 M) | (63.9 M) | (13.7 M) | 1.9 M | (37.9 M) | (42.6 M) | (471 K) | (11 M) | 145.5 M | 42 M | 15.9 M | 42 M | (99.6 M) | (114.5 M) | (108.8 M) |
| MDXG | (16.7 K) | (10.2 M) | (7.7 M) | (4.1 M) | 6.2 M | 29.4 M | 12 M | 64.7 M | (30 M) | (30 M) | (49.3 M) | (12.3 M) | (30.2 M) | 67.4 M | 42.4 M | 48.8 M | 51.2 M |
| PLSE | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (2.8 M) | (9.5 M) | (25.6 M) | (37.5 M) | (46 M) | (49.7 M) | (63.2 M) | (59 M) | (42.2 M) | (53.6 M) | (48.2 M) | (50.6 M) |
| ATAI | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (169.8 M) | (167.8 M) | (152.4 M) | (40.2 M) | (149.3 M) | (134.3 M) | (141.1 M) |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
Collegium Pharmaceutical and related stocks such as Amphastar P, Dynavax Technologies, and Cronos Group Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Collegium Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Collegium Pharmaceutical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Collegium Pharmaceutical Competitive Analysis
The better you understand Collegium Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Collegium Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Collegium Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Collegium Pharmaceutical Competition Performance Charts
Five steps to successful analysis of Collegium Pharmaceutical Competition
Collegium Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Collegium Pharmaceutical in relation to its competition. Collegium Pharmaceutical's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Collegium Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Collegium Pharmaceutical's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Collegium Pharmaceutical, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Collegium Pharmaceutical position
In addition to having Collegium Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Farming Thematic Idea Now
Farming
Companies producing farming products and providing services for farmers. The Farming theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Farming Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Collegium Pharmaceutical Correlation with its peers. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.132 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.